Session

Medical therapy in IBD: A potpourri of options (Posters)

ADD-ON MULTIPLE SUBMUCOSAL INJECTIONS OF RNA OLIGONUCLEOTIDE GUT-1 TO TUMOR NECROSIS FACTOR-ANTAGONIST TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: AN INVESTIGATOR-INITIATED TRIAL
ADD-ON MULTIPLE SUBMUCOSAL INJECTIONS OF RNA OLIGONUCLEOTIDE GUT-1 TO TUMOR NECROSIS FACTOR-ANTAGONIST TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: AN INVESTIGATOR-INITIATED TRIAL

Medical therapy in IBD: A potpourri of options (Posters)  et al.

FIRST LINE BIOLOGIC THERAPY IN IBD: A PROPENSITY SCORE ANALYSIS OF 12,747 PATIENTS IN THE UK IBD BIORESOURCE
FIRST LINE BIOLOGIC THERAPY IN IBD: A PROPENSITY SCORE ANALYSIS OF 12,747 PATIENTS IN THE UK IBD BIORESOURCE

Medical therapy in IBD: A potpourri of options (Posters)  et al.

REAL-WORLD EFFECTIVENESS AND SAFETY OF COMBINATION BIOLOGICS AND SMALL MOLECULE THERAPY IN INFLAMMATORY BOWEL DISEASE – A MULTICENTRE STUDY
REAL-WORLD EFFECTIVENESS AND SAFETY OF COMBINATION BIOLOGICS AND SMALL MOLECULE THERAPY IN INFLAMMATORY BOWEL DISEASE – A MULTICENTRE STUDY

Medical therapy in IBD: A potpourri of options (Posters)  et al.

SECOND LINE BIOLOGIC THERAPY IN IBD: A PROPENSITY SCORE ANALYSIS OF 3,410 PATIENTS IN THE UK IBD BIORESOURCE
SECOND LINE BIOLOGIC THERAPY IN IBD: A PROPENSITY SCORE ANALYSIS OF 3,410 PATIENTS IN THE UK IBD BIORESOURCE

Medical therapy in IBD: A potpourri of options (Posters)  et al.

COMPARATIVE EFFECTIVENESS OF BIOLOGICS IN PREVENTING PENETRATING COMPLICATIONS IN CROHN’S DISEASE
COMPARATIVE EFFECTIVENESS OF BIOLOGICS IN PREVENTING PENETRATING COMPLICATIONS IN CROHN’S DISEASE

Medical therapy in IBD: A potpourri of options (Posters)  et al.

IMPACT OF PRIOR BIOLOGIC EXPOSURE ON THE DURABILITY OF 3-YEAR CONTINUOUS OZANIMOD TREATMENT
IMPACT OF PRIOR BIOLOGIC EXPOSURE ON THE DURABILITY OF 3-YEAR CONTINUOUS OZANIMOD TREATMENT

Medical therapy in IBD: A potpourri of options (Posters)  et al.

NETWORK META-ANALYSIS TO EVALUATE THE COMPARATIVE EFFICACY OF BIOLOGICS FOR MAINTENANCE TREATMENT OF ADULT PATIENTS WITH CROHN’S DISEASE
NETWORK META-ANALYSIS TO EVALUATE THE COMPARATIVE EFFICACY OF BIOLOGICS FOR MAINTENANCE TREATMENT OF ADULT PATIENTS WITH CROHN’S DISEASE

Medical therapy in IBD: A potpourri of options (Posters)  et al.

REAL-WORLD COMPARISON OF EFFECTIVENESS BETWEEN USTEKINUMAB AND VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS EXPOSED TO AT LEAST ONE ANTI-TNF AGENT
REAL-WORLD COMPARISON OF EFFECTIVENESS BETWEEN USTEKINUMAB AND VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS EXPOSED TO AT LEAST ONE ANTI-TNF AGENT

Medical therapy in IBD: A potpourri of options (Posters)  et al.

DURABILITY AND SAFETY OF UPADACITINIB IN CROHN’S DISEASE AND ULCERATIVE COLITIS IN REAL LIFE: PRELIMINARY RESULTS FROM A SPANISH NATIONWIDE STUDY
DURABILITY AND SAFETY OF UPADACITINIB IN CROHN’S DISEASE AND ULCERATIVE COLITIS IN REAL LIFE: PRELIMINARY RESULTS FROM A SPANISH NATIONWIDE STUDY

Medical therapy in IBD: A potpourri of options (Posters)  et al.

IMPACT OF USTEKINUMAB ON EXTRAINTESTINAL MANIFESTATIONS AND IMMUNOMEDIATED DISEASES IN A COHORT OF PATIENTS WITH ULCERATIVE COLITIS IN REAL LIFE: THE ULISES STUDY
IMPACT OF USTEKINUMAB ON EXTRAINTESTINAL MANIFESTATIONS AND IMMUNOMEDIATED DISEASES IN A COHORT OF PATIENTS WITH ULCERATIVE COLITIS IN REAL LIFE: THE ULISES STUDY

Medical therapy in IBD: A potpourri of options (Posters)  et al.

ADD-ON MULTIPLE SUBMUCOSAL INJECTIONS OF RNA OLIGONUCLEOTIDE GUT-1 TO TUMOR NECROSIS FACTOR-ANTAGONIST TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: AN INVESTIGATOR-INITIATED TRIAL
ADD-ON MULTIPLE SUBMUCOSAL INJECTIONS OF RNA OLIGONUCLEOTIDE GUT-1 TO TUMOR NECROSIS FACTOR-ANTAGONIST TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: AN INVESTIGATOR-INITIATED TRIAL

REAL-WORLD EFFECTIVENESS AND SAFETY OF COMBINATION BIOLOGICS AND SMALL MOLECULE THERAPY IN INFLAMMATORY BOWEL DISEASE – A MULTICENTRE STUDY
REAL-WORLD EFFECTIVENESS AND SAFETY OF COMBINATION BIOLOGICS AND SMALL MOLECULE THERAPY IN INFLAMMATORY BOWEL DISEASE – A MULTICENTRE STUDY

SECOND LINE BIOLOGIC THERAPY IN IBD: A PROPENSITY SCORE ANALYSIS OF 3,410 PATIENTS IN THE UK IBD BIORESOURCE
SECOND LINE BIOLOGIC THERAPY IN IBD: A PROPENSITY SCORE ANALYSIS OF 3,410 PATIENTS IN THE UK IBD BIORESOURCE

COMPARATIVE EFFECTIVENESS OF BIOLOGICS IN PREVENTING PENETRATING COMPLICATIONS IN CROHN’S DISEASE
COMPARATIVE EFFECTIVENESS OF BIOLOGICS IN PREVENTING PENETRATING COMPLICATIONS IN CROHN’S DISEASE

NETWORK META-ANALYSIS TO EVALUATE THE COMPARATIVE EFFICACY OF BIOLOGICS FOR MAINTENANCE TREATMENT OF ADULT PATIENTS WITH CROHN’S DISEASE
NETWORK META-ANALYSIS TO EVALUATE THE COMPARATIVE EFFICACY OF BIOLOGICS FOR MAINTENANCE TREATMENT OF ADULT PATIENTS WITH CROHN’S DISEASE

REAL-WORLD COMPARISON OF EFFECTIVENESS BETWEEN USTEKINUMAB AND VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS EXPOSED TO AT LEAST ONE ANTI-TNF AGENT
REAL-WORLD COMPARISON OF EFFECTIVENESS BETWEEN USTEKINUMAB AND VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS EXPOSED TO AT LEAST ONE ANTI-TNF AGENT

DURABILITY AND SAFETY OF UPADACITINIB IN CROHN’S DISEASE AND ULCERATIVE COLITIS IN REAL LIFE: PRELIMINARY RESULTS FROM A SPANISH NATIONWIDE STUDY
DURABILITY AND SAFETY OF UPADACITINIB IN CROHN’S DISEASE AND ULCERATIVE COLITIS IN REAL LIFE: PRELIMINARY RESULTS FROM A SPANISH NATIONWIDE STUDY

IMPACT OF USTEKINUMAB ON EXTRAINTESTINAL MANIFESTATIONS AND IMMUNOMEDIATED DISEASES IN A COHORT OF PATIENTS WITH ULCERATIVE COLITIS IN REAL LIFE: THE ULISES STUDY
IMPACT OF USTEKINUMAB ON EXTRAINTESTINAL MANIFESTATIONS AND IMMUNOMEDIATED DISEASES IN A COHORT OF PATIENTS WITH ULCERATIVE COLITIS IN REAL LIFE: THE ULISES STUDY

FIRST LINE BIOLOGIC THERAPY IN IBD: A PROPENSITY SCORE ANALYSIS OF 12,747 PATIENTS IN THE UK IBD BIORESOURCE
FIRST LINE BIOLOGIC THERAPY IN IBD: A PROPENSITY SCORE ANALYSIS OF 12,747 PATIENTS IN THE UK IBD BIORESOURCE

IMPACT OF PRIOR BIOLOGIC EXPOSURE ON THE DURABILITY OF 3-YEAR CONTINUOUS OZANIMOD TREATMENT
IMPACT OF PRIOR BIOLOGIC EXPOSURE ON THE DURABILITY OF 3-YEAR CONTINUOUS OZANIMOD TREATMENT

Item 1 - 20 / 20
1